GT Biopharma

Having failed with orlotamab, and with enoblituzumab’s potential narrowing, Macrogenics generates interest around MGC018.

IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.

November 23, 2020

Pivotal data at the upcoming Ash conference make Novartis’s asciminib one of the highlights for oncology watchers.

September 01, 2017

July 28, 2017

December 22, 2015

Latest Reports